Envoy Medical Files Definitive Proxy Statement

TL;DR

Envoy Medical (EMED) filed its proxy statement for the annual meeting. Shareholders vote soon.

AI Summary

Envoy Medical, Inc. filed a definitive proxy statement (DEF 14A) on October 4, 2024, for its fiscal year ending December 31, 2024. The filing pertains to the company's annual meeting and related matters. Envoy Medical, previously known as Anzu Special Acquisition Corp I until January 15, 2021, is headquartered in White Bear Lake, MN.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the company's annual meeting, including any proposed resolutions, director elections, and executive compensation details, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new financial risks.

Key Numbers

• 001-40133 — SEC File Number (Identifies the specific SEC filing for Envoy Medical, Inc.)

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant
• Anzu Special Acquisition Corp I (company) — Former company name
• October 4, 2024 (date) — Filing date
• 20241114 (date) — Period of report
• 861369123 (company) — IRS Number

FAQ

Filing Documents

• ea0215993-01.htm (DEF 14A) — 678KB
• tproxy_001.jpg (GRAPHIC) — 1035KB
• tproxy_002.jpg (GRAPHIC) — 886KB
• 0001213900-24-085572.txt ( ) — 3326KB

From the Filing

DEF 14A 1 ea0215993-01.htm PROXY STATEMENT    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ SCHEDULE 14A _________________________________ Proxy Statement Pursuant to Section 14(a) (Rule 14a-101) of the Securities Exchange Act of 1934 Filed by the Registrant   Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2))   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material Pursuant to §240.14a -12 Envoy Medical, Inc. (Name of Registrant as Specified in its Charter) ______________________________________________________________ (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box):   No fee required.   Fee paid previously with preliminary materials.   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11 .   Envoy Medical, INC. 4875 White Bear Parkway White Bear Lake, MN 55110 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON November 14, 2024 TO THE STOCKHOLDERS OF Envoy Medical, INC.: Please Take Notice that Envoy Medical, Inc. (“Envoy Medical” or the “Company”) will hold its 2024 Annual Meeting of Stockholders at Delta Hotels Minneapolis Northeast, 1330 Industrial Blvd NE, Minneapolis, Minnesota, on November 14, 2024 at 3:00 p.m. local time. Envoy Medical is holding this meeting for the purpose of considering and taking appropriate action with respect to the following: 1.        To elect two Class I director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve until the earlier of the 2027 annual meeting of stockholders, the election of such director’s successor, or such director’s death, resignation or removal; 2.        To ratify the appointment of Grant Thornton LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2024; 3.        To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation; 4.        To recommend, on an advisory basis, the frequency of votes on named executive officer compensation; and 5.        To transact any other business as may properly come before the meeting or any adjournments thereof, including matters incident to the conduct of the meeting. Holders of record of Envoy Medical Class A Common Stock at the close of business on September 18, 2024 will be entitled to vote at the meeting or any adjournments thereof. Your attention is directed to the Proxy Statement accompanying this Notice for a more complete statement of the matters to be considered at the meeting. A copy of the Annual Report on Form 10 -K for the year ended December 31, 2023 also accompanies this Notice.   By Order of the Board of Directors,     /s/ Chuck R. Brynelsen Date: October 4, 2024   Chairman of the Board of Directors Your vote is important. To vote your shares, please vote by telephone or Internet, as directed in the Proxy Statement, or if you received a proxy card or voting instruction form by mail, please complete, sign, date and mail the proxy card or voting instruction form promptly in the envelope provided. The prompt return of proxies will save Envoy Medical the expense of further requests for proxies. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER   14, 2024: This Notice, the Proxy Statement, and the Annual Report on Form 10 -K are available at www.proxyvote.com and on the Investor Relations section of Envoy Medical’s website at ir.envoymedical.com .   Envoy Medical, INC. 4875 White Bear Parkway White Bear Lake, MN 55110 PROXY STATEMENT 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON November 14, 2024 This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of Envoy Medical, Inc., a Delaware corporation (“Envoy Medical,” the “Company,” “we,” “our” or “us”), for use at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at Delta Hotels Minneapolis Northeast, 1330 Industrial Blvd NE, Minneapo

View Full Filing

View this DEF 14A filing on SEC EDGAR